Can Medifast's New Compensation Plan Accelerate Coach Growth?

MED is reshaping its coach network around Executive Directors as productivity rises despite a sharp decline in active earning coaches.

Zacks Investment Research • Aug 21, 2026

Can Medifast's Coach Productivity Gains Help Revive Revenue Growth?

MED's improving coach productivity and client retention point to stabilization, but a shrinking coach base remains a challenge.

Zacks Investment Research • Aug 12, 2026

Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?

Medifast's Trilivy launch and cost cuts could support a Q4 profit turnaround, but shrinking revenue and its coach base keep risks high.

Zacks Investment Research • Aug 7, 2026

MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?

Medifast stock gains 13.6% in a month as improving coach productivity and earnings expectations support momentum despite weaker revenue.

Zacks Investment Research • Aug 7, 2026

Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?

Medifast's low valuation and improving coach productivity offer potential, but a shrinking coach base and weak growth keep the turnaround high risk.

Zacks Investment Research • Aug 7, 2026

Medifast: Worth A Speculative Entry As Sales Stabilize (Rating Upgrade)

Medifast, Inc. has started to report stabilizing sales through improved coach productivity, shown again in the Q2 report. Stabilized sales provide a pathway to stabilize earnings. MED targets profitability by Q4 already, but the target has to be taken with caution. Due to MED's $15.2 in net cash per share, the stock seems attractive. I estimate 44% upside to $18.8 on the condition that earnings improve near breakeven.

Seeking Alpha • Aug 6, 2026

Medifast Q2 Loss Narrower Than Expected, Coach Productivity Improves

MED tops Q2 earnings expectations despite lower sales, as rising coach productivity helps offset pressure from a shrinking coach network.

Zacks Investment Research • Aug 4, 2026

Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript

Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 4, 2026

Medifast Q2 Earnings Call Highlights

Medifast NYSE: MED reported second-quarter 2026 revenue of $76.4 million, down 27.6% from a year earlier, as its active earning coach base continued to decline amid the rapid adoption of GLP-1 medications across the traditional weight-loss category. The company posted a net loss of $3.1 million, or $0.28 per diluted share, compared with net income of $2.5 million, or $0.22 per share, in the prior-year quarter.

MarketBeat • Aug 4, 2026

Medifast Announces Second Quarter 2026 Financial Results

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, today reported results for the second quarter ended June 30, 2026. Second Quarter 2026 Revenue: $76.4 million, with revenue per active earning coach of $6,529 Independent active earning coaches of 11,700 Net loss of $3.1 million or $0.28 loss per diluted share ("EPS") Cash, Cash Equivalents, and Investment Securities of $169.8 million wit.

Business Wire • Aug 3, 2026